tgAAC94: Preliminary Phase I data

Preliminary data from a dose-escalation, placebo-controlled, U.S. and Canadian Phase I trial in 15 patients showed that intra-articular injection of tgAAC94 was well tolerated at doses up to 1x10 11 D...